Neuroprotective and neurorestorative properties of GDNF

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Gash, Don M ^a,c   Zhang, Zhiming ^a   Gerhardt, Greg ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

BLOOD BRAIN BARRIER; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0031662603     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440718     Document Type: Conference Paper

References (35)

1. Lin L-FH, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132
2. Lin L-FH, Zhang TJ, Collins F, Armes LG. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J Neurochem 1994;63:758-768
3. Moore MW, Klein RD, Fariñas I, et al. Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996;382:76-79
4. Pichel JG, Shen L, Sheng HZ, et al. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996;382:73-76
5. Sánchez MP, Silos-Santiago I, Frisén J, He B, Lira SA, Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996;382:70-73
6. Trupp M, Belluardo N, Funakoshi H, Ibanez C. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor α indicates multiple mechanisms of trophic actions in the adult CNS. J Neurosci 1997;17:3553-3567
7. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial cell line-derived neurotrophic factor. Nature 1996;384:467-470
8. GFRα Nomenclature Committee. Nomenclature of GPI-linked receptors for the GDNF ligand family. Neuron 1997;19:485
9. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1986;45:1-18
10. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 1993;60:140-147
11. Hoffer BJ, Hoffman A, Bowenkamp K, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994; 182:107-111
12. Bowenkamp KE, Hoffman AF, Gerhardt GA, et al. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 1995;355: 479-489
13. Lapchak PA, Miller PJ, Collins F, Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison ot intraventricular and intranigral delivery. Neuroscience 1997;78: 61-72
14. Hoffman AF, van Horne CG, Eken S, Hoffer BJ, Gerhardt GA. In vivo microdialysis studies of somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF. Exp Neurol 1997;147:130-141
15. Lapchak PA, Jiao S, Collins F, Miller PJ. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res 1997; 747:92-102
16. Tomac A, Lindqvist E, Lin L-FH, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373:335-339
17. Hudson J, Granholm A-C, Gerhardt GA, et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 1995;36:425-432
18. Hebert MA, Van Horne CG, Hoffer BJ, Gerhardt GA. Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J Pharmacol Exp Ther 1996;279:1181-1190
19. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980
20. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394
21. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 1986;39:7-16
22. Ovadia A, Zhang Z, Gash DM. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging 1995;16:931-937
23. Gash DM, Zhang Z, Cass WA, et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 1995;363:345-358
24. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380: 252-255
25. Miyoshi Y, Zhang Z, Ovadia A, et al. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 1997;42:208-214
26. Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997;282:1396-1401
27. Delong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285
28. Double KL, Crocker AD. Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc Natl Acad Sci USA 1995;92:1669-1673
29. Tseng JL, Baetge EE, Zurn AD, Aebischer P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J Neurosci 1997;17:325-333
30. Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 1997;17:7111-7118
31. Cass WA. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J Neurosci 1996;16:8132-8139
32. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995;373:339-341
33. Winkler C, Sauer H, Lee CS, Bjorklund A. Short-term GDNF treatment provides long term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1996;16:7206-7215
34. Choi-Lundberg DL, Lin Q, Chang Y-N, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838-841
35. Bilang-Bleuel A, Revah F, Colin P, et al. Intrastriaral injection of an adenoviral vectot expressing glial cell line-derived neurorrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc Narl Acad Sci USA 1997;94:8818-8823